Features of metabolic correction in patients after percutaneous coronary intervention for acute coronary syndrome without ST elevation

Abstract

Aim. Coronary artery disease (CAD) with concomitant metabolic syndrome (MS) leads to early disability and poor prognosis after urgent percutaneous coronary intervention (PCI) for acute coronary syndrome without elevation ST (ACS noST). Mathods and results. With the aim of treatment effectiveness improvement, 64 patients were treated (M : F = 55 : 9, mean age 66.9±12.4 years) in two regimens – standard (group I) and with metabolic supplement (group II). Patients in groups didn`t differ in the major clinical, anamnestic, laboratory and instrumental parameters. It was found, that in the II group (n= 33), those patients received in addition to the standard therapy quercetin, 40 mg three times daily for 12.07±1.51 months, compared with the group I (n=31), number of patients with MS` criteria decreased to 48.5% (n=16) and 77.4% (n=24), respectively. These results were obtained by reducing the waist circumflex of patients in the group II compared to the group I (p=0.034) and body mass index (p=0.048); improvement of insulin resistance (calculated by index HOMA) in group II patients in comparison to the group I (p=0.049), fasting blood glucose (p=0.024), low density lipoproteins (p=0.049) and plasma thrombin (p=0.0002). High density lipoproteins were significantly higher in group II patients compared to the group I (p=0.049). Conclusions: Long-term quercetin use in addition to standard therapy in patients with CAD and MS after PCI on the ACS without ST leads to the improvement of the system of metabolism due to the correction of the parameters of the metabolic syndrome.

Keywords

• Metabolic Diseases
• Quercetin
• Percutaneous Coronary Intervention
• Myocardial Ischemia